An uncharged oxetanyl sulfoxide as a covalent modifier for improving aqueous solubility.
暂无分享,去创建一个
Peter Wipf | P. Wipf | M. Kazancioglu | Joshua R Sacher | Erin M. Skoda | Erin M Skoda | Mustafa Z Kazancioglu | Jaideep Saha | Jaideep Saha | Joshua R. Sacher
[1] G. Lajoie,et al. Preparation of 1-[N-benzyloxycarbonyl-(1S)-1-amino-2-oxoethyl]-4-methyl-2,6,7-trioxabicyclo[2.2.2] octane: [Carbamic acid, [1-(4-methyl-2,6,7-trioxabicyclo[2.2.2]oct-1-yl)-2-oxoethyl]-, phenylmethyl ester, (S)-] , 2002 .
[2] Peter Wipf,et al. Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D. , 2011, ACS medicinal chemistry letters.
[3] B. Lucht,et al. ETHEREAL SOLVATION OF LITHIUM HEXAMETHYLDISILAZIDE : UNEXPECTED RELATIONSHIPS OF SOLVATION NUMBER, SOLVATION ENERGY, AND AGGREGATION STATE , 1995 .
[4] Minoru Ishikawa,et al. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. , 2011, Journal of medicinal chemistry.
[5] R B Greenwald,et al. PEG drugs: an overview. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[6] Gregory W. Kauffman,et al. Evaluating the differences in cycloalkyl ether metabolism using the design parameter "lipophilic metabolism efficiency" (LipMetE) and a matched molecular pairs analysis. , 2013, Journal of medicinal chemistry.
[7] E. Carreira,et al. Oxetanes as versatile elements in drug discovery and synthesis. , 2010, Angewandte Chemie.
[8] B. Hudson,et al. Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. , 2012, Journal of medicinal chemistry.
[9] G. Amidon,et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. , 2004, Molecular pharmaceutics.
[10] A. Parekh,et al. Receptors involved in mechanical responses to catecholamines in the circular muscle of guinea‐pig stomach treated with meclofenamate , 1990, British journal of pharmacology.
[11] Matthew S. Johnson,et al. Large-scale asymmetric synthesis of the bioprotective agent JP4-039 and analogs. , 2011, Organic letters.
[12] P. Wipf,et al. Design, Synthesis, and Biological Evaluation of PKD Inhibitors , 2011, Pharmaceutics.
[13] Hong Wang,et al. The mitochondria-targeted nitroxide JP4-039 augments potentially lethal irradiation damage repair. , 2009, In vivo.
[14] Melissa M. Sprachman,et al. A bifunctional dimethylsulfoxide substitute enhances the aqueous solubility of small organic molecules. , 2012, Assay and drug development technologies.
[15] D. Small,et al. Solubility of Bile Salts , 1969, Nature.
[16] E. Carreira,et al. Synthesis and stability of oxetane analogs of thalidomide and lenalidomide. , 2013, Organic letters.
[17] Li Di,et al. Bridging solubility between drug discovery and development. , 2012, Drug discovery today.
[18] G L Amidon,et al. Dissolution of acidic and basic compounds from the rotating disk: influence of convective diffusion and reaction. , 1986, Journal of pharmaceutical sciences.
[19] P. Wipf,et al. Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system. , 2005, Organic & biomolecular chemistry.
[20] Hannu Raunio,et al. Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.
[21] Nicolas Foloppe,et al. Drug-like Annotation and Duplicate Analysis of a 23-Supplier Chemical Database Totalling 2.7 Million Compounds , 2004, J. Chem. Inf. Model..
[22] P. Wipf,et al. Synthesis of analogs of the radiation mitigator JP4-039 and visualization of BODIPY derivatives in mitochondria. , 2013, Organic & biomolecular chemistry.
[23] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[24] Franz Schuler,et al. Oxetanes in drug discovery: structural and synthetic insights. , 2010, Journal of medicinal chemistry.
[25] C. Wermuth. Preparation of Water-Soluble Compounds by Covalent Attachment of Solubilizing Moieties , 2008 .
[26] G. Lajoie,et al. Preparation of 1‐[N‐Benzyloxycarbonyl‐(1S)‐1‐Amino‐2‐Oxoethyl]‐4‐Methyl‐2,6,7‐Trioxabicyclo[2.2.2]Octane , 2003 .
[27] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[28] L. Pustilnik,et al. Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors. , 2011, Journal of medicinal chemistry.
[29] W. Fischer,et al. Über Steroide. (33. Mitteilung). Über Glucoside des Desoxycorticosterons , 1942 .
[30] M. Kansy,et al. Solubility-Excipient Classification Gradient Maps , 2007, Pharmaceutical Research.
[31] K. J. Mysels,et al. Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. , 1992, Journal of lipid research.